Efficacy, safety and pharmacokinetics of raltegravir in patients with HIV infections and cancer receiving antineoplastic chemotherapy

Trial Profile

Efficacy, safety and pharmacokinetics of raltegravir in patients with HIV infections and cancer receiving antineoplastic chemotherapy

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Nov 2015

At a glance

  • Drugs Raltegravir (Primary) ; Abacavir; Antineoplastics; Emtricitabine; Lamivudine; Tenofovir disoproxil fumarate
  • Indications HIV infections
  • Focus Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 09 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top